If I am in the mood, I enjoy it: An exploration of cancer-related fatigue and sexual functioning in women with breast cancer

Oncologist

Volumn 16, Issue 9, 2011, Pages 1333-1344

  Webber, Kate ^a,b   Mok, Kelly ^a   Bennett, Barbara ^a,b   Lloyd, Andrew R ^b   Friedlander, Michael ^a,c   Juraskova, Ilona ^d   Goldstein, David ^a,c  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Breast neoplasms; Fatigue; Quality of life; Sexual dysfunction

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISABILITY; DISEASE ASSOCIATION; EMOTIONAL STABILITY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MOOD; MOOD DISORDER; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; SELF REPORT; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUAL SATISFACTION; SEXUALITY;

BREAST NEOPLASMS; FATIGUE; FEMALE; HUMANS; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SEXUAL BEHAVIOR;

EID: 80053191906     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0100     Document Type: Article

References (60)

1. Avis NE, Crawford S, Manuel J. Quality of life among younger women with breast cancer. J Clin Oncol 2005;23:3322-3330.
2. Barni S, Mondin R. Sexual dysfunction in treated breast cancer patients. Ann Oncol 1997;8:149-153.
3. Meyerowitz BE, Desmond KA, Rowland JH et al. Sexuality following breast cancer. J Sex Marital Ther 1999;25:237-250.
4. Ganz PA, Rowland JH, Desmond K et al. Life after breast cancer: Understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998;16:501-514.
5. Lindley C, Vasa S, Sawyer WT et al. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 1998;16:1380-1387.
6. Mortimer JE, Boucher L, Baty J et al. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol 1999;17:1488-1492.
7. Cella D, Fallowfield L, Barker P et al. Quality of life of postmenopausal women in the ATAC ("Arimidex", Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006;100:273-284.
8. Fallowfield LJ, Bliss JM, Porter LS et al. Quality of life in the Intergroup Exemestane Study: A randomized trial of exemestane versus continued ta-moxifen after2 to 3 years of tamoxifen inpostmenopausal women with primary breast cancer. J Clin Oncol 2006;24:910-917.
9. Malinovszky KM, Gould A, Foster E et al. Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancer. Br J Cancer 2006;95:1626-1631.
10. Ganz PA, Desmond KA, Belin TR et al. Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 1999;17:2371-2380.
11. Burwell SR, Case LD, Kaeline C et al. Sexual problems in younger women after breast cancer surgery. J Clin Oncol 2006;24:2815-2821.
12. Berglund G, Nystedt M, Bolund C et al. Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: A prospective randomized study. J Clin Oncol 2001;19:2788-2796.
13. Ganz PA, Kwan L, Stanton AL et al. Quality of life at the end of primary treatment of breast cancer: First results from the moving beyond cancer randomized trial. J Natl Cancer Inst 2004;96:376-387.
14. Panjari M, Bell RJ, Davis SR. Sexual function after breast cancer. J Sex Med 2011;8:294-302.
15. Mok K, Juraskova I, Friedlander M. The impact of aromatase inhibitors on sexual functioning: Current knowledge and future research directions. Breast 2008;17:436-440.
16. Ganz PA, Desmond KA, Leedham B et al. Quality of life in long-term, disease-free survivors of breast cancer: A follow-up study. J Natl Cancer Inst 2002;94:39-49.
17. Bower JE, Ganz PA, Desmond KA et al. Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. J Clin Oncol 2000;18: 743-753.
18. Glaus A, Boehme C, Thrlimann B et al. Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol 2006;17:801-806.
19. Goldstein D, Bennett B, Friedlander M et al. Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: A longitudinal study. BMC Cancer 2006;6:240.
20. Bennett B, Goldstein D, Lloyd A et al. Fatigue and psychological distress- exploring the relationship in women treated for breast cancer. Eur J Cancer 2004;40:1689-1695.
21. Alexander S, Minton O, Andrews P et al. A comparison of the characteristics of disease-free breast cancer survivors with or without cancer-related fatigue syndrome. Eur J Cancer 2009;45:384-392.
22. Goldstein D, Bennett BK, Cameron B et al. A prospective cohort study of fatigue after adjuvant therapy for breast cancer: Association with hemato-logic, endocrine, and immune parameters. J Clin Oncol 2008;26(15 suppl): 9596.
23. Webber K, Goldstein D, Bennett BK et al. Late fatigue after adjuvant therapy for breast cancer is largely unrelated to cancer or its treatment: 5 year followup ofaprospective cohort study. Asia PacJ Clin Oncol 2010;6(suppl 2):59-60.
24. Ganz PA, Schag CA, Lee JJ et al. The CARES: A generic measure of health-related quality of life for patients with cancer. Qual Life Res 1992; 1:19-29.
25. Schover LR, Jensen SB. Sexuality and Chronic Illness: A Comprehensive Approach. New York: Guilford Press, 1988:126-134.
26. Schag CA, Heinrich RL, Aadland RL et al. Assessing problems of cancer patients: Psychometric properties of the cancer inventory of problem situations. Health Psychol 1990;9:83-102.
27. Ganz PA, Schag CA, Cheng HL. Assessing the quality of life-a study in newly-diagnosed breast cancer patients. J Clin Epidemiol 1990;43:75-86.
28. Goldberg D, Williams P. A Users Guide to the General Health Questionnaire. Windsor, U.K.: NFER-Nelson Publishing Company, 1998:1-129.
29. Hadzi-Pavlovic D, Hickie IB, Wilson AJ et al. Screening for prolonged fatigue syndromes: Validation of the SOFA scale. Soc Psychiatry Psychiatr Epidemiol 2000;35:471-479.
30. Hickie I, Koschera A, Hadzi-Pavlovic D et al. The temporal stability and co-morbidity of prolonged fatigue: A longitudinal study in primary care. Psychol Med 1999;29:855-861.
31. Hickie I, Davenport T, Vernon SD et al. Are chronic fatigue and chronic fatigue syndrome valid clinical entities across countries and health-care settings? Aust N Z J Psychiatry 2009;43:25-35.
32. Hickie IB, Davenport TA, Hadzi-Pavlovic D et al. Developmentof asimple screening tool for common mental disorders ingeneral practice. Med JAust 2001;175(suppl):S10-S17.
33. Hickie IB, Davenport TA, Naismith SL et al. SPHERE: A national depression project. SPHERE National Secretariat. Med J Aust 2001;175(suppl): S4-S5.
34. Hickie IB, Davenport TA, Naismith SL et al. Conclusions about the assessment and management of common mental disorders in Australian general practice. SPHERE National Secretariat. Med J Aust 2001;175(suppl):S52- S55.
35. Koschera A, Hickie I, Hadzi-Pavlovic D et al. Prolonged fatigue, anxiety and depression: Exploring relationships in a primary care sample. Aust N Z J Psychiatry 1999;33:545-552.
36. Hickie I, Davenport T, Wakefield D et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: Prospective cohort study. BMJ 2006;333:575-580.
37. Graham PH, Browne L, Cox H et al. Inhalation aromatherapy during radiotherapy: Results of a placebo-controlled double-blind randomized trial. J Clin Oncol 2003;21:2372-2376.
38. Stockler MR, O'Connell R, Nowak AK et al. Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: A placebo-controlled double-blind randomised trial. Lancet Oncol 2007;8:603-612.
39. Clover K, Leigh Carter G, Adams C et al. Concurrent validity of the PSYCH-6, a very short scale for detecting anxiety and depression, among oncology outpatients. Aust N Z J Psychiatry 2009;43:682-688.
40. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992;30: 473-483.
41. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-263.
42. McHorney CA, Ware JE, Lu JF et al. The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40-66.
43. Brazier JE, Harper R, Jones NM et al. Validating the SF-36 health survey questionnaire: New outcome measure for primary care. BMJ 1992;305: 160-164.
44. Australian Bureau of Statistics. National Health Survey: SF-36 Population Norms Australia. Canberra, Australia: Australian Bureau of Statistics, 1995:1-37.
45. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
46. Coates A, Porzsolt F, Osoba D. Quality of life in oncology practice: Prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer 1997;33:1025-1030.
47. Blatt MHG, Wiesbader H, Kupperman HS. Vitamin E and climacteric syndrome: Failure of effective control as measured by menopausal index. Arch Intern Med 1953;91:792-799.
48. Alder E. The Blatt-Kupperman menopausal index: A critique. Maturitas 1998;29:19-24.
49. Carpenter JS, Andrykowski MA. Menopausal symptoms in breast cancer survivors. Oncol Nurs Forum 1999;26:1311-1317.
50. Melby MK. Climacteric symptoms among Japanese women and men: Comparison of four symptom checklists. Climacteric 2006;9:298-304.
51. Palacios S, Castelo-Branco C, Cancelo MJ et al. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. Maturitas 2005;50:98-104.
52. Von Korff M, Ustun TB, Ormel J et al. Self-report disability in an international primary care study of psychological illness. J Clin Epidemiol 1996; 49:297-303.
53. Young-McCaughan S. Sexual functioning in women with breast cancer after treatment with adjuvant therapy. Cancer Nurs 1996;19:308-319.
54. Speer JJ, Hillenberg B, Sugrue DP et al. Study of sexual functioning determinants in breast cancer survivors. Breast J 2005;11:440-447.
55. Ganz PA, Greendale GA, Petersen L et al. Managing menopausal symptoms in breast cancer survivors: Results of a randomized controlled trial. J Natl Cancer Inst 2000;92:1054-1064.
56. Rowland JH, Meyerowitz BE, Crespi CM et al. Addressing intimacy and partner communication after breast cancer: A randomized controlled group intervention. Breast Cancer Res Treat 2009;118:99-111.
57. Thirlaway K, Fallowfield L, Cuzick J. The Sexual Activity Questionnaire: A measure of women's sexual functioning. Qual Life Res 1996;5:81-90.
58. Jensen PT, Klee MC, Thranov I et al. Validation of a questionnaire for self-assessment of sexual function and vaginal changes after gynaecological cancer. Psychooncology 2004;13:577-592.
59. Rosen R, Brown C, Heiman J et al. The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191-208.
60. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. JAMA 1999;281:537-544.